Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer.
Dai Y, Yang L, Sakandar A, Zhang D, Du F, Zhang X, Zou L, Zhao Y, Wang J, Zhang Z, Wu X, Li M, Ling X, Yu L, Dong L, Shen J, Xiao Z, Wen Q.
Dai Y, et al. Among authors: wang j.
Front Oncol. 2022 Nov 29;12:906197. doi: 10.3389/fonc.2022.906197. eCollection 2022.
Front Oncol. 2022.
PMID: 36524001
Free PMC article.